Royal Bank of Canada (NYSE:RY) is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 97,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada’s biggest bank, and one of the largest in the world based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our 17 million clients in Canada, the U.S. and 27 other countries.
RBC Capital analyst Tom Narayan reiterates General Motors (NYSE:GM) with a Outperform and maintains $48 price target.
RBC Capital maintains General Motors (NYSE:GM) $48 price target Read Post »
RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $490 to $580.
RBC Capital raises Eli Lilly (NYSE:LLY) price target from $490 to $580 Read Post »
RBC Raises Price Target on Jacobs Solutions (NYSE:J) to $157 From $152, Cites ‘Good Quarter With Potential Catalysts,’ Keeps Outperform Rating。
RBC Raises Price Target on Jacobs Solutions (NYSE:J) to $157 From $152 Read Post »
RBC Capital analyst Andrew Wong reiterates Mosaic (NYSE:MOS) with a Sector Perform and maintains $40 price target.
RBC Capital maintains Mosaic (NYSE:MOS) $40 price target Read Post »
RBC Raises Price Target on Albemarle (NYSE:ALB) to $260 From $255 on 2023 Guidance Boost Amid Higher Lithium Pricing; Outperform Kept。
RBC Raises Price Target on Albemarle (NYSE:ALB) to $260 From $255 Read Post »
RBC Cuts Price Target on Target (NYSE:TGT) to $161 From $191, Expects ‘Messy’ Fiscal Q2 Results, Keeps Outperform Rating。
RBC Cuts Price Target on Target (NYSE:TGT) to $161 From $191 Read Post »
RBC Capital Lifts Price Target on Walmart (NYSE:WMT) to $165 From $164 Amid Boost to Fiscal Q2 Earnings Estimate ‘to Better Reflect Expense Leverage,’ Keeps Outperform Rating。
RBC Capital Lifts Price Target on Walmart (NYSE:WMT) to $165 From $164 Read Post »
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $83 to $84.
RBC Capital raises Gilead Sciences (NASDAQ:GILD) price target from $83 to $84 Read Post »
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $379 to $374.
RBC Capital lowers Biogen (NASDAQ:BIIB) price target from $379 to $374 Read Post »
RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250, Maintains Sector Perform Rating.
RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250 Read Post »
RBC Capital Raises Price Target on MetLife (NYSE:MET) to $74 From $70, Maintains Outperform Rating.
RBC Capital Raises Price Target on MetLife (NYSE:MET) to $74 From $70 Read Post »
RBC Capital Cuts Price Target on Moderna (NASDAQ:MRNA) to $190 From $200, Maintains Outperform Rating.
RBC Capital Cuts Price Target on Moderna (NASDAQ:MRNA) to $190 From $200 Read Post »